Login to Your Account

Icagen Spikes 38% on Positive Data for Epilepsy Compound

By Donna Young

Wednesday, March 17, 2010
Investors were more than relieved Tuesday on the news that Icagen Inc.'s ICA-105665 met its primary endpoint in a Phase IIa study measuring the drug's ability to reduce the photic-induced epileptiform EEG response in patients with epilepsy. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription